Stem Cell Clinic

OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients |…

By adminApril 22, 2020Stell Cell Research

DetailsCategory: AntibodiesPublished on Wednesday, 22 April 2020 10:00Hits: 146

ROCKVILLE, MD, USA I April 21, 2020 I OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients (SAC-COVID) at the University of Maryland Baltimore Medical Center on April 20, 2020. The national trial will involve at least 10 medical centers throughout the nation. Dr. Shyamasundaran Kottilil, Professor of Medicine, Director, Division of Clinical Care and Research at the Institute of Human Virology at the University of Maryland School of Medicine is the Principal Investigator of the trial and Dr. Joel Chua, Assistant Professor of Medicine, Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine is the clinical principle investigator for the University of Maryland Medical Center. ClinSmart, LLC of Newton, Pennsylvania is the Clinical Research Organization contracted to manage the trial.

The new trial will test the impact of OncoImmunes flagship product, CD24Fc, in dampening inflammation caused by virus-induced cellar injuries, which is likely a major underlying cause of cytokine storm, immune dysfunction and pneumonia observed in severe COVID-19 patients. A cohort of 230 subjects with severe clinical symptoms will be randomized and administered a single dose of CD24Fc (480 mg by IV infusion) or placebo and followed over a 28-day period to assess safety and efficacy in clinical improvement. As the drug has a novel mechanism of action, it will likely synergize with other drugs, including antiviral treatments such as chloroquine and Remdesivir, or other immune modulators targeting cytokines or their receptors. Therefore, the trial will accept patients undergoing, or intending to enroll in trials testing other experimental therapies.

OncoImmune is grateful to Dr. Kottilil and the University of Maryland Baltimore for leading the clinical effort, said Martin Devenport, the Chief-operating Officer of OncoImmune. It took only 12 days from FDA approval to get the trial started and we could not have achieved this without the dedicated staff from the University and the CRO, added Raymond Touomou, Vice President for Clinical Operations.

About OncoImmune, Inc.

OncoImmune (www.oncoimmune.com) is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. OncoImmune is based in Rockville, Maryland.

OncoImmunes lead product, CD24Fc, is a novel therapeutic that regulates host inflammatory response to tissue injuries and which has broad implications in the pathogenesis of cancer, autoimmune disease, metabolic syndrome and graft-versus-host disease (GVHD). CD24Fc has completed a Phase IIa trial for the prophylactic treatment of acute GVHD in leukemia patients undergoing hematopoietic stem cell transplantation (HSCT) and resulted in a significant improvement in 180 Day Grade III-IV acute GVHD Free Survival, the Phase III primary endpoint. CD24Fc prophylaxis also resulted in reduced relapse and, compared to match controls, CD24Fc demonstrated improvement in Overall Survival, Non-Relapse Mortality and Relapse-Free Survival. A dose-dependent reduction in severe (Grade > 3) mucositis was also observed. A 20 patient open label dose expansion cohort at the recommended clinical dose is fully enrolled and the drug continues to perform very well. A Phase III study for the prevention of acute GVHD is anticipated to start in mid-2020.

SOURCE: OncoImmune

See the article here:
OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients |...

Research Antibodies Market Global Opportunity Analysis and Forecast 2018-2028 Cole Reports – Cole of Duty

By adminApril 22, 2020Stell Cell Research

Global Research Antibodies Market: Overview

The global research antibodies market is predicted to be a progressive one over the forecast period. The exceptional physiological properties of antibodies make them sought-after for cell research. Antibodies have the ability to bind to specific molecules, which allows molecules of interest to be isolated for cell research. This is a key factor for continual research to study the anatomy and physiology of antibodies.

Order Brochure for more Detailed Information @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4440

The report serves readers to gauge prevailing trends and future growth opportunities in the global research antibodies market. It comprises the most relevant data pertaining to market dynamics. A detailed analysis of the competitive landscape is a key feature of the report.

Global Research Antibodies Market: Key Trends

At present, the number of R&D activities carried out by pharmaceutical and biopharmaceutical companies to introduce novel products is on the rise. These pursuits involve the use of antibodies that exhibit exceptional physiological properties. This, in turn is boosting research on antibodies for their use for secondary cell research.

Hefty investments from pharmaceutical giants for advancement of antibodies research is also boosting the research antibodies market.

Furthermore, increasing incidence of cancer and other chronic diseases is encouraging research organizations and pharmaceutical and biotechnology companies to develop advanced therapeutics and personalized medicine. The use of antibodies for early detection of cancer is also increasingly recognized. These factors collectively are stimulating the research antibodies market.

Besides this, increasing public and private initiatives and adequate funds for stem cell research are aiding the growth of research antibodies market.

Request TOC for Facts & Tables @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4440

Global Research Antibodies Market: Market Potential

In a new development, the FDA has approved the clinical use of DNA-encoded monoclonal antibody (DMAb) therapy to prevent Zika virus infection. Unlike conventional therapeutic antibodies manufactured in industrial units, DMAb employed for the therapy is made inside the body. Patients are administered DNA instructions for the body to equip itself with necessary tools, and make its own highly specific antibodies to fight infection. The antibodies produced fight pathogenic targets such as virus-infected cells, bacteria, and cancer cells.

DMAb therapy is bringing about a clinical change in antibody therapy. Over the recent past, detailed preclinical studies using DMAb have been conducted, resulting in successful in vivo production of DMAb. The new approach displays extensive potential for major advancement over traditional monoclonal antibody therapy. Further, DMAb therapy could broaden the spectrum of antibody therapeutics, thereby opening new patient markets for antibody-based therapies for disease prevention or treatment.

Global Research Antibodies Market: Regional Outlook

North America holds supremacy among the key regions for research antibodies globally. Presence of a large number of biopharmaceutical and biotechnology companies coupled with immense government support for research are key factors behind the growth of North America research antibodies market. In addition, manufacturers of antibodies need to adhere to stringent guidelines for high quality products. This provides enhance reliability for researchers and clinicians involved in antibodies research and secondary cell research.

Asia Pacific is expected to display remarkable growth in the research antibodies market over the forecast period. Increasing R&D and adoption of novel techniques for antibodies production is serving to boost this region. Furthermore, improving healthcare infrastructure and implementation of stringent quality adherence policies by public organizations in emerging economies is spurring growth of Asia Pacific research antibodies market.

Global Research Antibodies Market: Competitive Landscape

Some key companies operating in the global research antibodies market are Abcam PLC, Thermo Fisher Scientific Inc., and Agilent Technologies. Top companies in the market are adopting novel growth strategies to sustain the highly competitive environment.

Avail the Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=4440

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Visit link:
Research Antibodies Market Global Opportunity Analysis and Forecast 2018-2028 Cole Reports - Cole of Duty

Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Surfacing Magazine

By adminApril 21, 2020Induced Pluripotent Stem Cells

DataIntelo report titled Global Induced Pluripotent Stem Cells Market provides detailed information and overview about the key influential factors required to make well informed business decision. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Request Free Sample Report of Induced Pluripotent Stem Cells Market Report @ https://dataintelo.com/request-sample/?reportId=77310

Induced Pluripotent Stem Cells Market Report Includes:

For More Information on This Report Visit @ https://dataintelo.com/enquiry-before-buying/?reportId=77310

By Product Types:HepatocytesFibroblastsKeratinocytesAmniotic CellsOthers

The report is further broken down into various segments such as product types, applications, and regions.

By Applications:Academic ResearchDrug Development And DiscoveryToxicity ScreeningRegenerative Medicine

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

The Induced Pluripotent Stem Cells Market Report Covers the Following Companies:Fujifilm Holding CorporationAstellas PharmaFate TherapeuticsBristol-Myers Squibb CompanyViaCyteCelgene CorporationAastrom BiosciencesAcelity HoldingsStemCellsJapan Tissue EngineeringOrganogenesis

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants understand the competitive scenario to plan future strategies.

To Purchase This Report: https://dataintelo.com/checkout/?reportId=77310

The Report Provides:

The Induced Pluripotent Stem Cells Market Report Addresses the Following Queries:

For Best Discount on Purchasing this Report Visit https://dataintelo.com/ask-for-discount/?reportId=77310

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: sales@dataintelo.comWebsite: https://dataintelo.com

Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 – WhaTech Technology and Markets News

By adminApril 21, 2020Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells Market research report provides the details about Industry Chain structure, Market Competition, Market Size & Share, SWOT Analysis, Technology, Cost, Raw Materials, Consumer Preference, Development & Trends, Regional Forecast, Company & Profile, and Product & Service.

This Induced Pluripotent Stem Cells Market research report is focused on providing its reader with all the necessary details that can help them make necessary business decisions. It provides wholesome information that is necessary to understand the market inside-out.

ReportsnReports has recently added a new research report to its expanding repository. The research report, titled Induced Pluripotent Stem Cells Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis.

The research study also looks specifically at the need for Induced Pluripotent Stem Cells Market.

Download A Sample Report atwww.reportsnreports.com/contactme=2906851

Report Scope:

This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered.

For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of the World.

Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

Report Includes:

59 tables

An overview of the global market for induced pluripotent stem cells

Analyses of global market trends with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024

Information on induced pluripotent stem cell research products, including various assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes

Complete understanding of the key technologies adopted for induced pluripotent stem cell research

Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth

Profiles of major players in the industry, including Applied StemCell Inc., BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group Ltd., Promega Corp. and Thermo Fisher Scientific Inc.

Summary

It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years.

Particularly for the past five years, the global market for iPSCs has experienced a rapid growth. The market was estimated at REDACTED in 2018 and over REDACTED in 2019, with an average REDACTED growth.

The overall iPSC market is forecast to continue its steady growth and reach REDACTED in 2024, with anestimated compound annual growth rate (CAGR) of REDACTED from 2019 through 2024.

Key Drivers for Market Growth

This report has identified several key drivers for the rapidly growing market

iPSCs hold promising hope for therapeutic solutions for diseases without ethical issues. A series of technical breakthroughs were made in recent years for improving cellular reprogramming, differentiation and large-scale production of GMP- grade iPSCs derived cells toward clinical usability.

Advances in genetics such as NGS technologies have promoted the progress on precision medicine, where the availability of iPSCs from a variety of genetic, lifestyle and environment backgrounds will help make the precision healthcare a clinical reality. iPSC banking together with related technologies is developing into a platform for precision and personalized medicine, which is experiencing rapid growth globally.

In recent years, several iPSCs clinical trials have been or are going to be launched for a variety of diseases. The first human iPSC clinical trial started in August 2014, and the recent report of the first macular degeneration patient treated with the sheets of retinal pigmented epithelial cells made from iPSCs was encouraging.

The progresses toward clinical practice will drive the growth of the clinical market and the research market as well.

The pharmaceutical industry needs better cell sources such as iPSC-derived functional cells for drug toxicity testing and drug screening.

The U.S. government has been encouraging the marketing of stem cells, including iPSCs.

The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinsons and Huntingtons using stem cells.

The provisions of grants from organizations, such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) have been encouraging for the research institutes to venture into iPSC research.

Rapidly growing medical tourism and contract research outsourcing drives the Asia-Pacific stem cell market.

Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize.

New biotechnologies such as CRISPR/Cas genome editing technology are advancing iPSCs into more and better uses. For example, the hypoimmunogenic derivatives of engineered iPSCs have shown lost immunogenicity which would become a potential novel therapy to treat various diseases.

Please Share Your Specific Interest To Serve You Better | Download PDF Brochure atwww.reportsnreports.com/contactme=2906851

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Induced Pluripotent Stem Cells Market. Different strategies implemented by these vendors have been analyzed and studied in order to gain a competitive edge, create unique product portfolios and increase their market share.

The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players.

In addition, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

Scope of the Report:

Through following the Induced Pluripotent Stem Cells Market through depth, the readers should find this study very helpful. The aspects and details are depicted by charts, bar graphs, pie diagrams, and other visual representations in theInduced Pluripotent Stem Cells Market study.

This intensifies the representation of the pictures and also helps to improve the facts of the Induced Pluripotent Stem Cells Market industry. At a substantial CAGR, the Induced Pluripotent Stem Cells Market is likely to grow.

Induced Pluripotent Stem Cells Market reports main objective is to guide the user to understand the market in terms of its definition, classification, industry potential, the latest trends, and the challenges facing the Induced Pluripotent Stem Cells Market.

Access Full Report atwww.reportsnreports.com/purchasme=2906851

And More

This email address is being protected from spambots. You need JavaScript enabled to view it.

Original post:
Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 - WhaTech Technology and Markets News

The Best Face and Body Skin-Care Products for 2020 – Shape Magazine

By adminApril 21, 2020Platelet Rich Plasma Injections

When our panelists were asked which innovation showed the best results, scalp injections of platelet-rich plasma (PRP) for hair growth was at the top of many lists. You get significant benefits with very little downside, Dr. Schultz says. First, your blood is drawn and spun in a centrifuge to separate the PRP, which is then injected all over your scalp. Using your bloods growth factors to stimulate collagen and follicles lets your own body work its magic, says dermatologist Mona Gohara, M.D.

Another new option is a laser called Lutronic KeraLase ($750 to $1,000 per treatment), which is paired with a synthetic growth factor serum. The device stamps across your scalp, stimulating the area and creating tiny channels in the follicles, where the serum is then applied. It delivers active ingredients where theyre needed, says dermatologist Jeanine Downie, M.D. The serum can contain even more growth factors than a persons own PRP, plus stem cells to help hair growth, she says. Nutrafol for Women (Buy It, $79 $88 for 1 month, nutrafol.com), a supplement brand for hair loss, also garnered multiple mentions from our panel. Ive seen promising results, especially in conjunction with the above treatments, Dr. Downie says.

Read the original post:
The Best Face and Body Skin-Care Products for 2020 - Shape Magazine

Stem Cell Therapy: A Promising Treatment for COVID-19? – Technology Networks

By adminApril 21, 2020Stem Cell Medical Center

Stem cell therapy is making its way into COVID-19 treatment. Its use seems to be particularly efficient in the case of severely ill patients, as demonstrated by a study conducted at the Beijing YouAn Hospital recently published in the peer reviewed journalAging and Disease, and as emerged after the press conference hold by Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the Ministry of Science and Technology.Bioscience Institute a company specializing in stem cell isolation, expansion and cryopreservation reported the results of the Beijing study on the diseases associated with novel coronavirus (SARSCoV-2) infection as they were anticipated before their publication. Now its authors confirm that The intravenous transplantation of MSCs [Mesenchymal Stem Cells] was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition. And according to Sun Yanrong, stem cell treatment has already been used in more than 200 cases in the most affected city in China, Wuhan.Stem cell treatment: how it worksStem cell treatment efficacy lies on the immunomodulatory effect of stem cells. In particular, as emerged from theAging and Diseasestudy, MSCs may help counteract the so-called cytokine storm, an uncontrolled rise of the immune response resulting in the increase of inflammation mediators (cytokines).

During a cytokine storm the immune system goes into overdrive and the patient's tissues and organs can be fatally damaged. Acute respiratory distress syndrome (ARDS) is a common sign of a cytokine storm. In COVID-19 patients it corresponds to the severe oxygen deprivation that requires mechanical ventilation.

Cytokine storm seems to be a good target for severe COVID-19 cases treatment. Nowadays, other drugs, such as tocilizumab, act on this phenomenon. In particular, tocilizumab has already been approved both in China and the USA for the treatment of severe COVID-19 and is used in clinical trials in Europe.Stem cells against COVID-19: beyond ChinaStem cell treatment has already crossed Chinas borders too. A few days before Sun Yanrong pressconference, the US Food and Drug Administration (FDA) opened the way to the compassionate use ofMSCs intravenous infusions in patients with COVID-19 ARDS and a very dismal prognosis.

There are lots of clinical trials that explored, or are planning to explore, immunomodulatory andanti-inflammatory properties of MSCs, Giuseppe Mucci, CEO of Bioscience Institute, highlights.

Cytokines are important mediators of the inflammatory process, and MSCs are believed toregulate their production. In particular, they seem to be involved in the downregulation ofproinflammatory cytokines and in the upregulation of anti-inflammatory cytokines. Their use issafe, and studies in larger cohorts of patients will validate their benefits.

Bioscience Institute is ready to contribute to this validation. We are working on a protocol for aMSCs treatment with stem cells isolated and expanded at our facilities. With our long-standingexperience in the field of stem cells isolation, expansion and cryopreservation, Bioscience Institutelaboratories are among the most advanced in the world.

Compassionate use of MSCs approved by FDA will utilize allogeneic (from a donor) stem cells.However, anyone can build up its own MSCs reserve. They can be easily obtained from severaltissues, but fat is considered the best source ever, Mucci explains. To obtain the huge cellnumbers needed for COVID-19 treatment it is fundamental MSCs expansion. That is why it is notsufficient to rely on a cell bank: only a cell factory like Bioscience Institute is able to guarantee thebanking of a quantity of MSCs useful for such a treatment.

More:
Stem Cell Therapy: A Promising Treatment for COVID-19? - Technology Networks

Israeli COVID-19 treatment with 100% survival rate tested on US patient – The Jerusalem Post

By adminApril 21, 2020Stem Cell Medical Center

Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the countrys compassionate use program.The news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristems placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.In the US case, the patient was treated with the companys PLX cell therapy at Holy Name Medical Center in New Jersey, where Pluristem is already running a Phase III critical limb ischemia study. Like the patients treated in Israel, this patient was critically ill with respiratory failure due to acute respiratory distress syndrome and was intubated in an intensive care unit for three weeks.The companys president and CEO, Yaky Yanay, said that although Pluristem is focused on a planned multinational clinical trial for the treatment of complications associated with coronavirus, it does hope to expand treatment under compassionate use in other countries at the same time.

Specifically, the US treatment was administered under the US Food and Drug Administrations Single Patient Expanded Access Program, which is part of the US Coronavirus Treatment Acceleration Program - an emergency program aimed at getting treatments to corona patients as quickly as possible.

In Israel, the six patients were treated at three different Israeli medical centers for one week, also under a compassionate use program. They were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the six patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.

Pluristems PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties, meaning they induce the immune systems natural regulatory T cells and M2 macrophages, the company explained in a previous release. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).

Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.

We are pleased with this initial outcome of the compassionate use program and committed to harnessing PLX cells for the benefit of patients and healthcare systems, Yanay said.

Meet the 5 female finalists for the 2020 M&T Bank John Travers Award – PennLive

By adminApril 21, 2020Stem Cell Medical Center

For the 39th year, M&T Bank, in conjunction with PennLive and the Harrisburg Lions Club, has been honoring central Pa.s top student-athletes with the John Travers Award.

The 2020 finalists have all excelled as athletes, students, and voices in their communities. Today, we shine a spotlight on the 5 female finalists.

Winners will be announced next month along with the A.I. Garner Outstanding Coach Award winner. The Travers Award is named for the late executive sports editor of The Patriot-News.

Gabriella Recce, Central Dauphin

Gabriella Recce Central Dauphin track and field during media day on February 28, 2019.Sean Simmers | ssimmers@pennlive.comPENNLIVE.COM

Varsity sports: Track and Field (4 letters), Indoor Track (3 letters), Golf (4 letters), Cheerleading (1 letter), Swimming (1 letter)

College choice: University of Virginia

Finalists voice: I chose to pursue engineering as my career, because engineers can change the way we live in the world. Whether eradicating cancer and other debilitating diseases, improving our health with stem cell therapies, cleaning the environment with sustainable approaches or creating novel transportation methods, engineers are trained to solve problems and generate new solutions. My passion for this career comes from my dedication to my academic journey, my learning as a multi-event athlete and the support and encouragement of my family.

Describe yourself in one word: Positive

Gabriella Recce of Central Dauphin competes in the girls 3A long jump during the District 3 Track & Field Championships at Shippensburg University on May 18, 2019.Joe Hermitt | jhermitt@pennlive.com

Accomplishments: Theres no question Recce was aligned for a terrific final season in track and field. Earning three PIAA medals in the pole vault, long jump and triple jump at last years PIAA Championship meet, Recce was poised to add a few more records to her already glowing career. Shes earned a dozen top finishes during Mid-Penn and District 3 competitions. Plus, she qualified and competed at the prestigious Penn Relays, New Balance Outdoor and Indoor National competitions along the way. Recce was coming off an outstanding Indoor season when the spring sports calendar was canceled due to the coronavirus pandemic. Reece, also an accomplished golfer, helped the Rams golf team win a District 3 title in 2017. Vice-President of CDs National Honors Society, Recce also served as Editor of the Key Club and volunteered with PAWS, LPGA Girls Golf of Harrisburg, the Four Diamonds Club and PanRam Field Day for special needs students. In addition, the senior won a national gold medal in scholastic art and writing (2016) and was part of Hershey Medical Centers PULSE Program.

Katie Sajer, Trinity

Katie Sajer (20) of Trinity girls basketball during Mid-Penn basketball media day on Nov. 14, 2019.Dan Gleiter | dgleiter@pennlive.com

Varsity sports: Volleyball (4 letters), Basketball (4 letters), Lacrosse (4 letters)

College choice: University of Notre Dame

Finalists voice: The ROTC program offers chances to earn skill sets and exposure otherwise unavailable to civilians. These skills will be necessary to ensure the lives and safety of my team. By using my athleticism in this regard, I will be able to give back to the country that has made me into the person I am today, and fight for the people who came before me. I will be able to make a larger impact through this use of my athleticism than anything I would be able to do on the athletic field or court.

Describe yourself in one word: Hard-working

Trinity's Katie Sajer drives past a Central Dauphin defender during Central Dauphins 55-42 win over Trinity in the Mid-Penn girls basketball championship, February 13, 2020.Vicki Vellios Briner | Special to PennLiveVicki Vellios Briner | Special to PennLive

Accomplishments: Among the most versatile athletes in the Mid-Penn Conference, Sajer captained a pair of Trinity sports programs and is a two-time All-State pick in volleyball. In fact, Sajer was a 2019 nominee for the Under Armour High School All-American volleyball team. Awarded a national four-year Army ROTC Scholarship at Notre Dame, Duke University, the University of Delaware and Bucknell University, Sajer opted to focus on physical, mental and leadership training in South Bend. Sajer has worked as marketing intern for Pennsylvania Wounded Warriors, developing a campaign that has raised approximately $145,000 to support servicemen and women in Pa. Sajer, a member of Trinitys French Foreign Language Honors Society, also served as a property manager in her family business, and worked as a school mentor and activities leader.

Gery Schnarrs, East Pennsboro

Gery Schnarrs of East Pennsboro field hockey during high school football media day on July 31, 2019.Sean Simmers | ssimmers@pennlive.com

Varsity sports: Field Hockey (4 letters), Track and Field (2 letters)

College choice: University of Virginia

Finalists voice: I would tell young athletes to stay at it. Obviously, you are going to face a lot of obstacles. You are going to think a lot of times that, maybe if you dont make a team, you should move on to something different? I think its important to stay at it and keep following what you want to do. I think thats how you succeed. If you want to do it, then I think thats where youre going to put most of your effort.

Describe yourself in one word: Determined

Gery Schnarrs, East Pennsboro M/D (Univ. of Virginia). The Mid-Penn is overflowing with field hockey players who will take their talents to the next level. Oct. 24, 2019. Sean Simmers | ssimmers@pennlive.com

Accomplishments: Ever since the Virginia recruit broke onto the field hockey scene, scoring 10 goals with 12 assists as a freshman, Schnarrs has impacted the Mid-Penn Conference and beyond. A current member of USA Womens National Indoor Development team, Schnarrs capped her brilliant run with a spot on Max Field Hockeys HS All-American team. She holds East Pennsboro career mark with 198 points and earned multiple All-State appointments. The Panthers won four straight division titles, and four trips to states, with No. 37 digging in. A Scholar of Distinction on the National Field Hockey Coaches Association Academic team, Schnarrs has served as treasurer for three different school programs, including that National Honors Society. A Girl Scouts Gold Award winner through her Get in the Game initiative. Schnarrs also won a Silver Presidential Volunteer Service Award last year and coordinated multiple service drives like Purses for a Purpose for the homeless and a bedding rive for the Speranza Animal Shelter. Shes also volunteered with the Bethesda Mission Womens Shelter, Salvation Army and more.

Marlee Starliper, Northern

Northern's Marlee Starliper shows off her NC State gear Sunday after committing to the Wolfpack.

Varsity sports: Cross Country (4 letters), Track and Field (4 letters), Indoor Track (4 letters)

College choice: North Carolina State

Finalists voice: I aspire to run professionally after college with the hope of having a long career in which I can pursue qualifying for several Olympic teams. Another aspect of y athletic goals is to continue enjoying the sport, have fun discovering more of my capabilities, and be a positive impact within the running community and beyond.

Describe yourself in one word: Passionate

Northern's Marlee Starliper trails Greencastle's Taryn Parks in the AAA 1600 meter run during day 2 of the 2019 PIAA Track and Field Championships at Shippensburg University. May 25, 2019 Sean Simmers | ssimmers@pennlive.comPENNLIVE.COM

Accomplishments: Starlipers resume is overflowing with state and national records, including three consecutive PIAA cross country titles. She was runner-up as a freshman. Pa.s Gatorade Cross County Player of the Year three times, Starliper also twice claimed Foot Locker Northeast regional titles and was runner-up at Foot Locker Nationals in the fall. She now holds the states all-time mark. On the track, Starliper is a four-time state champion and her mile (4:37) and 3k (9:07) standards rank No. 1 nationally. Invited to the Reykjavik Games in Iceland by the National Scholastic Athletic Foundation, Starliper finished third in the 800. Shes also competed for USATF in the Pan-American Games in Costa Rica, becoming a U20 national champion. An active member of the World Harvest Outreach Church in Chambersburg, Starliper has participated in Direct Call, a student-led Christian group at Northern, volunteered as a Special Olympics buddy and served a regular speaker to middle school cross country and tracks teams about nutrition. Recently, Starliper signed to write and illustrate a childrens book in Spanish.

Maddie Zimmer, Hershey

Maddie Zimmer, Hershey MF (Northwestern). The Mid-Penn is overflowing with field hockey players who will take their talents to the next level. Oct. 24, 2019. Sean Simmers | ssimmers@pennlive.com

Varsity sports: Field Hockey (4 letters), Lacrosse (3 letters)

College choice: Northwestern University

Finalists voice: This winter Ive actually been helping to coach at multiple field hockey clubs. I never thought I would like it, but I actually really like coaching the little girls. I didnt think I had the patience for it, but they improved so much and its so rewarding to see how excited they are. Thats how I was when I was their age. All I wanted to do was play field hockey and its so exciting to be a part of their journey. Its so rewarding and fun to watch.

Describe yourself in one word: Dedicated

Hershey's Maddie Zimmer brings the ball down field against Lower Dauphin in their high school field hockey game at Hershey. Sept. 11, 2019.Sean Simmers | ssimmers@pennlive.com

Accomplishments: As one of the nations top field hockey players in her class, Zimmer is a four-time All-State pick and high school All-American in her final two seasons. The midfielder also led the Trojans to the PIAA Class 3A title in 2018. She also earned US Lacrosse All-American honors as a junior. Continuing to rehab an ACL tear she suffered in November, Zimmer is planning to compete for the U21 U.S. National Field Hockey Team against Ireland in June. Her first cap came against Canada last summer. After Ireland will be the Junior Pan American Games in Chile, an official qualifier for the 21 Junior World Cup. Continuing to make an impact in her community, Zimmer has coached youth field hockey and lacrosse programs, donated her time to Purses full of Hope, raised funds for the Walk for Clean Water Organization and co-chaired the Herren Project, a non-profit that supports families with addiction and prevention of substance abuse.

2020 Travers Award female nominees

Follow Eric Epler on Twitter -- @threejacker

Thanks for visiting PennLive. Quality local journalism has never been more important. We need your support. Not a subscriber yet? Please consider supporting our work.

Regenerative Medicine Market With Economic Growth And Five Forces Analysis By 2024 – Kentucky Journal 24

By adminApril 21, 2020Stem Cell Medicine

Overview: Regenerative medicine is an interdisciplinary field that applies life science and engineering principles for the regeneration or repair of injured/diseased tissues or organs resulting from various causes including, disease, defects, trauma and aging. The field includes the generation and use of tissue engineering, therapeutic stem cells and the production of artificial organs. It also allows scientists to grow organs or tissues in the lab and implant them in the body safely when the body fails to heal itself. Notably, it has great potential to solve the problem of organ shortage. According to the estimation of World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, that has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.

Request for Report sample : https://www.trendsmarketresearch.com/report/sample/9918

The market for regenerative medicine is driven by increasing prevalence of neuronal disease, cancer and genetic disease, emerging application of regenerative medicine, and advancement in technology. Huge number of ongoing clinical trails and strong product pipeline are providing market growth oppurtunity. High cost of the treatment, regulatory issues and ethical issuesare hampering the market growth.

Market Analysis: The Global Regenerative Medicine market is estimated to witness a CAGR of 16.6% during the forecast period 20182024. The global market is analyzed based on three segments Therapy, Application and regions.

Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global regenerative medicine market, followed by Europe. Asia-Pacific region is expected to have the fastest growth rate with the market growth centered at Japan, China and India. This is mainly due to increasing funding in healthcare research, rising research activities, growing patient pool, flexible regulatory environment for clinical trials, and rising healthcare expenditure.

Therapy Analysis: Immunotherapy occupied major market share of global regenerative medicine market in 2017, and is expected to remain same during the forecasted period. Increasing product approvals, emerging technological advancements in cell and gene therapy, flexible regulatory for stem cell based research, and growing awareness regarding the benefits of stem cell therapies.

Application Analysis: The market by application is segmented into cancer, central nervous system, orthopedic and musculoskeletal, diabetes, dermatology, cardiovascular and others. Among various application, dermatology occupied the largest share in 2017 and cancer segment is expected to grow at fastest rate during the forecasted period. Growing aging population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.

Key Players: Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporation and other predominate and niche players.

Request for Report Discount: https://www.trendsmarketresearch.com/report/discount/9918

Competitive Analysis: Currently dermatology segment dominates the global regenerative medicine segment. A lot of researches are going on cancer, CNS, cardiovascular, orthopedic & musculoskeletal applications. The increasing importance of regenerative medicine has resulted in the launch of new products and also increased acquisition, approvals, funding to develop new product. For instance, in August 2017, Tissue Regenix Group plc completed the acquisition of acquisition of CellRight Technologies, an US based specialist in regenerative osteoinductive bone scaffolds. In April 2018, Roche acquired a program named Inception 5, focused on regenerative therapies for multiple sclerosis. In May 2018, Novartis received second FDA approval for Kymriah, CAR-T cell therapy for B-cell acute lymphoblastic leukemia (ALL).

Make an Inquiry before Buying@: https://www.trendsmarketresearch.com/checkout/9918/Single

Benefits: The report provides complete details about the usage and adoption rate of regenerative medicine in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

What to do if you think you have COVID-19: a step by step guide – The Dickinson Press

By adminApril 21, 2020Stem Cell Clinic

If you've become ill and are experiencing symptoms such as fever, cough or difficulty breathing, call your physician prior to going to any clinic. He or she will screen you over the phone and prepare the clinic to accept you.

"Usually they're taken straight back to the room so they can be tested, and sometime they're tested in their car, depending on each facility's protocols," said Brett Kallis, director of nurses for Southwest District Health Unit.

Your sample will be sent to the state laboratory in Bismarck for testing, and you should have results within two to three days, provided to you by your health provider.

While waiting for your test results, you should self-isolate in your home and separate yourself from others in your household as much as possible. If you cannot completely separate yourself from others in your home, the North Dakota Department of Health advises you to avoid close contact.

"Do not snuggle, kiss or share food or drink and remember to wash your hands often. Avoid sharing dishes, cups, utensils, towels, bedding and other personal items in the home until they can be washed with soap and water. Clean all high-touch surfaces (counters, tabletops, doorknobs, toilets, phones, etc.) at least daily if not more often. Utilize household cleaning sprays and wipes according to the label instructions. Face masks can be worn when around other people or pets."

If your test results indicate that you are positive for COVID-19, continue to remain in your home, separate yourself from others in your home and monitor your symptoms. If you experience any of the following warning signs, call your health care provider immediately: difficulty breathing or shortness of breath, persistent pain or pressure in the chest, new confusion or inability to arouse, bluish lips or face.

A contract tracer will contact you for a list of people with whom you've been in contact since two days prior to the onset of your symptoms. They will then call those people, and you and them will need to self-isolate and monitor your symptoms. A public health worker will contact you once a day for you to report your symptoms.

Do not share drinks, utensils, bedding, towels or other personal items with others, and wash them after use. Wash your hands often with soap and water for at least 20 seconds, especially after blowing your nose, sneezing, coughing or using the bathroom. Continue to disinfect shared surfaces.

Remain in isolation at home until risk of transmission is low. According to the health department, this means, "You must remain at home isolated until seven days have passed since your symptom onset and you have been fever-free (have a temperature below 100.4 degrees Fahrenheit) for 72 hours without the use of fever-reducing medications and respiratory symptoms are improving."

However, if you are a health care worker or immunocompromised (i.e., HIV, take immunosuppressive medications, stem cell or bone marrow transplant), you must also have two negative COVID-19 tests, 24 hours apart.

If your results are negative, you should still remain home until you are fever-free without the use of fever-reducing medications for at least 24 hours and your symptoms have improved.

"When someone would test negative, it means that their viral load isn't high enough, so there could be a possibility that they could be a false negative, so continuing to watch for symptoms and monitor is the best thing," Kallis said.

See the original post here:
What to do if you think you have COVID-19: a step by step guide - The Dickinson Press